Infographic: “Planet Trial: Intravitreal aflibercept monotherapy for Polypoidal Choroidal Vasculopathy (PCV)”

Document Type

Article

Publication Date

6-1-2022

Abstract

PCV Polypoidal choroidal vasculopathy, IAI Intravitreal aflibercept monotherapy1,2, rPDT rescue Photodynamic therapy, ETDRS Early treatment diabetic retinopathy study, ICG indocyanine green angiography.

Keywords

Angiogenesis inhibitors, Choroid, Data visualization, Fluorescein angiography, Humans, Intravitreal injections, Planets, Polyps, Receptors, Vascular endothelial growth factor, Recombinant fusion proteins, Tomography, optical coherence, Aflibercept, Aflibercept, Angiogenesis inhibitor, Fusion protein, Vasculotropin receptor, Adult, Article, Best corrected visual acuity, Controlled study, Double blind procedure, Drug efficacy, Drug safety, Female, Human, Loading drug dose, Major clinical study, Male, Middle aged, Monotherapy, Phase 3 clinical trial, Phase 4 clinical trial, Photodynamic therapy, Polypoidal choroidal vasculopathy, Randomized controlled trial, astronomy, Choroid, Fluorescence angiography, Intravitreal drug administration, Optical coherence tomography, Polyp

Publication Title

Eye

Divisions

ophthalmplogy

Funders

None

Volume

36

Issue

6

Publisher

Springer Nature

This document is currently not available here.

Share

COinS